Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
The private funding rose 38% amid growing international collaborations and CDMO demand
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
Domestic sales increased 15.5%, supported by the relaunch of previously recalled products in the market
Collaboration to drive diagnostics exports, tap high-growth regional markets and build scalable commercialization platform
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
Discussions are likely to centre on how the country can move up the pharmaceutical value chain
Subscribe To Our Newsletter & Stay Updated
